Proactive Research analyst Ed Stacey says Avacta (LON:AVCT) is preparing for a crucial year in its cancer therapeutics programmes in 2020, with an opportunity now identified for a targeted chemotherapy programme to enter clinical trials during the first half.
Stacey says alongside the recent release of their interim results, Avacta's announced a proposed equity placing of up to £9mln.
The biggest deployment of the new funds will be the AVA6000 pro-doxorubicin tumour-targeted chemotherapy programme developed via the Tufts collaboration.
